Overview of Pfizer's Recent Options Activity
Significant bearish sentiment is emerging from investors with substantial capital as they engage with options for Pfizer. Examining the options history for Pfizer (PFE), we can identify a total of 40 trades executed recently.
Out of these trades, about 35% reflect bullish expectations, while a notable 52% indicate a bearish approach. Specifically, there were 18 put options totaling approximately $881,278 against 22 call options worth around $1,564,167.
Price Movement Predictions
Analyzing the volume and open interest from recent contracts shows that the trading whales are targeting a price range between $20.00 and $30.00 for Pfizer over the last quarter. This data paints a more comprehensive picture of potential price movements.
Understanding Volume & Open Interest Dynamics
Evaluating volume and open interest is fundamental for stock analysis. This information is essential for assessing liquidity and gauging interest levels in Pfizer's options at various strike prices. Here’s a brief overview of the trends in volume and open interest for call and put options concerning Pfizer in the $20.00 to $30.00 strike price range over the last month.
Recent Options Trading Summary
Here’s a compilation of significant options trades observed recently regarding Pfizer:
- CALL - Sweeping action reflects bearish sentiment for options expiring on 12/20/2024, involving a strike price of $25.00 with substantial trading volume.
- CALL - Another bearish sentiment was noted for 01/16/2026, showing similar patterns with a strike price of $30.00.
- PUT - Emphasizing bearish expectations for 11/29/2024 at a $25.00 strike price also indicates notable capital movement.
- CALL - Neutral sentiment tracked for 06/20/2025 with a price range of $29.00.
- CALL - Highlighted bullish sentiments for 05/16/2025 with a lower risk reported at a $21.00 strike price.
About Pfizer
Pfizer stands as one of the leading pharmaceutical companies globally, with annual sales nearing $50 billion, excluding revenues tied to COVID-19 products. Although its portfolio historically covered a broad range of healthcare items, the current focus lies heavily on prescription medications and vaccines. Some of Pfizer’s premier products include the pneumococcal vaccine Prevnar 13, the cancer treatment Ibrance, and the cardiovascular medication Eliquis, with almost half of sales deriving from international markets, particularly growing economies.
Pfizer's Current Market Position
As we take a closer look at Pfizer's trading performance, recent statistics reveal:
- A trading volume reaching 34,661,607, currently witnessing a price adjustment to $24.88, down by -0.89%.
- RSI indicators suggest that the stock could be perceived as oversold at the moment.
- An earnings announcement is anticipated shortly, within about 69 days.
Expert Opinions on Pfizer
An average of three analysts weighed in on Pfizer's stock within the last month, establishing a target price of approximately $38.33. This analysis showcases the varied sentiments around the stock's potential future performance.
Frequently Asked Questions
What recent trends have emerged in Pfizer's options trading?
Recent data shows a shift towards bearish sentiment among traders, with a majority of put options being executed in relation to call options.
What price range is being targeted by options traders?
Traders have focused on a price movement target between $20.00 and $30.00 for Pfizer's stock over the past three months.
What do the volume and open interest indicate for Pfizer?
Volume and open interest help gauge the liquidity and current interest levels for options on various strike prices, giving insights into trading strategies.
How does Pfizer fare in the global pharmaceutical market?
As a major player, Pfizer generates close to $50 billion in annual sales, with significant contributions from international markets, especially in emerging economies.
What are analysts currently predicting for Pfizer's stock performance?
Analysts project a target price averaging around $38.33, reflecting a mix of cautious optimism and uncertainty in the stock's future valuation.
